Using a novel comprehensive therapeutic approach—first-line etoposide and carboplatin combined with volumetric-modulated arc therapy and maintenance antiangiogenic therapy, second-line immunotherapy with albumin-bound paclitaxel and carboplatin, and third-line etoposide and cisplatin with durvalumab—a patient with limited-stage small cell lung cancer has achieved and maintained a complete response for more than 32 months to date. The gene discussed is ALB; the disease is small cell lung carcinoma.